SGLT2i use is associated with an increased risk of DKA and UTI, but confers several favourable outcomes, notably preservation of renal function, reduced risk of developing heart failure and CKD, and of hospitalisation, despite a higher prevalence of heart failure, hypertension, IHD and CKD at baseline
revealed that liraglutide attenuated the phosphorylation of JAK2 and STAT3 in AGE-stimulated endothelial cells and the kidney of db/db mice (Zitman-Gal et al., 2019)
There is some data bearing this out
JMCP 27(3):354366 Trogdon JG, Finkelstein EA, Hylands T, Dellea PS, Kamal-Bahl SJ (2008) Indirect costs of obesity: a review of the current literature